High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
ASCO 2022
Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
LDCT Screening Tied to Lower Incidence of Advanced Lung Cancer
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
Camrelizumab, Apatinib, and Temozolomide Combo Produces Durable Responses in Acral Melanoma
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Treatment Advances for Metastatic Breast Cancer Tied to Decrease in Deaths
Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.
Acupuncture Improves Symptoms of Radiation-Induced Xerostomia in Head and Neck Cancer
Acupuncture was associated with improvements in symptoms and quality of life.
The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasm
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Rivoceranib Appears Active in Recurrent, Metastatic Adenoid Cystic Carcinoma
Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.
Toripalimab With Axitinib Active in Treatment-Naive Advanced Mucosal Melanoma
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
- Loading...
Loading...
Next post in ASCO 2022 Melanoma In-Depth
Loading... 
Loading...